JO984B1
(en)
|
1977-10-11 |
1979-12-01 |
بيتشام غروب ليمتد |
A dry pharmaceutical compound with a suitable dosage unit for oral administration
|
US4513006A
(en)
|
1983-09-26 |
1985-04-23 |
Mcneil Lab., Inc. |
Anticonvulsant sulfamate derivatives
|
US5998380A
(en)
|
1995-10-13 |
1999-12-07 |
New England Medical Center Hospitals, Inc. |
Treatment of migraine
|
US5952187A
(en)
|
1995-12-01 |
1999-09-14 |
Oxis International, Inc. |
Topiramate immunoassay
|
UA53655C2
(uk)
|
1996-06-28 |
2003-02-17 |
Орто-Макнейл Фармасьютікел, Інк. |
Спосіб лікування ожиріння
|
US5753693A
(en)
|
1996-06-28 |
1998-05-19 |
Ortho Pharmaceutical Corporation |
Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
|
RU2207854C2
(ru)
|
1996-06-28 |
2003-07-10 |
Орто-Макнейл Фармасьютикал, Инк. |
Способ лечения псориаза
|
US5753694A
(en)
|
1996-06-28 |
1998-05-19 |
Ortho Pharmaceutical Corporation |
Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
|
AU3501697A
(en)
|
1996-06-28 |
1998-01-21 |
Ortho Pharmaceutical Corporation |
Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
|
CA2267945C
(en)
|
1996-10-08 |
2005-05-17 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful in treating neuropathic pain
|
US6572880B2
(en)
|
1996-10-24 |
2003-06-03 |
Pharmaceutical Applications Associates Llc |
Methods and transdermal compositions for pain relief
|
CA2216215A1
(en)
|
1997-04-05 |
1998-10-05 |
Isa Odidi |
Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
|
US20080292700A1
(en)
|
1997-04-21 |
2008-11-27 |
Biovail Laboratories |
Controlled release formulations using intelligent polymers
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
JP4083818B2
(ja)
|
1997-06-06 |
2008-04-30 |
ディポメド,インコーポレイティド |
高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形
|
US7744916B2
(en)
|
1997-06-11 |
2010-06-29 |
Umd, Inc. |
Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
|
US5760006A
(en)
|
1997-06-23 |
1998-06-02 |
Ortho Pharmaceutical Corporation |
Anticonvulsant derivatives useful in treating psoriasis
|
US5760007A
(en)
|
1997-07-16 |
1998-06-02 |
Ortho Pharmaceutical Corporation |
Anticonvulsant derivatives useful in treating neuropathic pain
|
US5935933A
(en)
|
1997-07-16 |
1999-08-10 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful in treating neuropathic pain
|
US6622036B1
(en)
|
2000-02-09 |
2003-09-16 |
Cns Response |
Method for classifying and treating physiologic brain imbalances using quantitative EEG
|
UA65607C2
(uk)
|
1998-03-04 |
2004-04-15 |
Орто-Макнейл Фармацевтикал, Інк. |
Фармацевтична композиція (варіанти) та спосіб її приготування
|
EP1100504A2
(en)
|
1998-07-02 |
2001-05-23 |
Eisai Co., Ltd. |
Pharmaceutical compositions and their uses for treatment of demyelinating disorders
|
WO2000006096A1
(en)
|
1998-07-30 |
2000-02-10 |
The Procter & Gamble Company |
Hair care compositions
|
US6541520B1
(en)
|
1998-08-05 |
2003-04-01 |
Brookhaven Science Associates |
Treatment of addiction and addiction-related behavior
|
US6890951B2
(en)
|
1998-08-05 |
2005-05-10 |
Brookhaven Science Associates Llc |
Treatment of addiction and addiction-related behavior
|
JP2002527470A
(ja)
|
1998-10-20 |
2002-08-27 |
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド |
アルコール依存症、中毒及び乱用の処置に有用な抗痙攣剤誘導体
|
US20010055613A1
(en)
|
1998-10-21 |
2001-12-27 |
Beth A. Burnside |
Oral pulsed dose drug delivery system
|
EP1002535A1
(en)
|
1998-10-28 |
2000-05-24 |
Hrissanthi Ikonomidou |
New use of glutamate antagonists for the treatment of cancer
|
ATE261724T1
(de)
|
1998-11-17 |
2004-04-15 |
Ortho Mcneil Pharm Inc |
Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
|
US20020006908A1
(en)
|
1998-12-03 |
2002-01-17 |
Daniel P. Van Kammen |
Anticonvulsant derivatives useful in treating schizophrenia
|
US7214711B2
(en)
|
1998-12-23 |
2007-05-08 |
Neurotherapeutics Pharma Llc |
Method of treating migraine headache without aura
|
ES2228465T3
(es)
|
1999-01-19 |
2005-04-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Uso derivados anticonvulsionantes para el tratamiento de cefaleas en brotes.
|
AR022321A1
(es)
|
1999-01-21 |
2002-09-04 |
Ortho Mcneil Pharm Inc |
Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada
|
CA2360655C
(en)
*
|
1999-01-29 |
2007-03-20 |
Losan Pharma Gmbh |
Pharmaceutical compositions
|
BR0007897A
(pt)
|
1999-02-01 |
2001-10-30 |
Ortho Mcneil Pharm Inc |
Uso de derivados anticonvulsivantes para otratamento de bulimia nervosa
|
WO2000045812A1
(en)
|
1999-02-08 |
2000-08-10 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful in treating autism
|
ES2257288T3
(es)
|
1999-02-17 |
2006-08-01 |
Ortho-Mcneil Pharmaceutical, Inc. |
Derivados antiepilepticos utilizados en el tratamiento de temblor esencial.
|
ATE294577T1
(de)
|
1999-02-24 |
2005-05-15 |
Univ Cincinnati |
Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen
|
US6548529B1
(en)
|
1999-04-05 |
2003-04-15 |
Bristol-Myers Squibb Company |
Heterocyclic containing biphenyl aP2 inhibitors and method
|
US6201010B1
(en)
|
1999-04-08 |
2001-03-13 |
Ortho-Mcneil Pharmceutical, Inc. |
Anticonvulsant derivatives useful in lowering blood pressure
|
WO2000061140A1
(en)
|
1999-04-08 |
2000-10-19 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful in maintaining weight loss
|
CA2369093C
(en)
|
1999-04-08 |
2005-10-18 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful in lowering lipids
|
NZ514811A
(en)
|
1999-04-08 |
2005-01-28 |
Ortho Mcneil Pharm Inc |
Anticonvulsant derivatives useful in reducing blood glucose levels
|
AU4307800A
(en)
|
1999-04-30 |
2000-11-17 |
Merab Lomia |
New indication for use of antiepileptic agents and medicines
|
MXPA01011014A
(es)
|
1999-04-30 |
2003-06-30 |
Johnson & Johnson |
Derivados anticonvulsivos utiles en el tratamiento de dependencia de cocaina.
|
US6420369B1
(en)
|
1999-05-24 |
2002-07-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful in treating dementia
|
MXPA01012187A
(es)
|
1999-05-28 |
2002-06-21 |
Jeffrey Berlant |
Compuestos y metodos para el tratamiento del trastorno por estres postraumatico.
|
US7674776B2
(en)
|
1999-06-14 |
2010-03-09 |
Vivus, Inc. |
Combination therapy for effecting weight loss and treating obesity
|
US20080103179A1
(en)
|
2006-10-27 |
2008-05-01 |
Tam Peter Y |
Combination Therapy
|
US7659256B2
(en)
|
1999-06-14 |
2010-02-09 |
Vivus, Inc. |
Combination therapy for effecting weight loss and treating obesity
|
US20080255093A1
(en)
|
1999-06-14 |
2008-10-16 |
Tam Peter Y |
Compositions and methods for treating obesity and related disorders
|
US7056890B2
(en)
|
1999-06-14 |
2006-06-06 |
Vivus, Inc. |
Combination therapy for effecting weight loss and treating obesity
|
US7553818B2
(en)
|
1999-06-14 |
2009-06-30 |
Vivus, Inc. |
Combination therapy for effecting weight loss and treating obesity
|
WO2001013904A2
(en)
|
1999-08-20 |
2001-03-01 |
Ortho-Mcneil Pharmaceutical, Inc. |
Composition comprising a tramadol material and an anticonvulsant drug
|
US6414002B1
(en)
|
1999-09-22 |
2002-07-02 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
|
US6515117B2
(en)
|
1999-10-12 |
2003-02-04 |
Bristol-Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
US6887870B1
(en)
|
1999-10-12 |
2005-05-03 |
Bristol-Myers Squibb Company |
Heterocyclic sodium/proton exchange inhibitors and method
|
PH12000002657B1
(en)
|
1999-10-12 |
2006-02-21 |
Bristol Myers Squibb Co |
C-aryl glucoside SGLT2 inhibitors
|
US10179159B2
(en)
|
1999-10-22 |
2019-01-15 |
Scott Wepfer |
Topical anesthetic formulation
|
US6479467B1
(en)
|
1999-12-16 |
2002-11-12 |
Eastman Chemical Company |
Cyclodextrin ethers
|
AU767812B2
(en)
|
2000-02-04 |
2003-11-27 |
Depomed, Inc. |
Shell-and-core dosage form approaching zero-order drug release
|
SE0000601D0
(sv)
|
2000-02-24 |
2000-02-24 |
Jan Hedner |
Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
US6555519B2
(en)
|
2000-03-30 |
2003-04-29 |
Bristol-Myers Squibb Company |
O-glucosylated benzamide SGLT2 inhibitors and method
|
US6683056B2
(en)
|
2000-03-30 |
2004-01-27 |
Bristol-Myers Squibb Company |
O-aryl glucoside SGLT2 inhibitors and method
|
US20010036943A1
(en)
|
2000-04-07 |
2001-11-01 |
Coe Jotham W. |
Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
|
EP1157682A1
(en)
|
2000-05-25 |
2001-11-28 |
Cilag AG |
Blister package for topiramate tablets
|
US20020028826A1
(en)
|
2000-06-15 |
2002-03-07 |
Robl Jeffrey A. |
HMG-CoA reductase inhibitors and method
|
US20020013334A1
(en)
|
2000-06-15 |
2002-01-31 |
Robl Jeffrey A. |
HMG-CoA reductase inhibitors and method
|
WO2002000221A1
(en)
|
2000-06-23 |
2002-01-03 |
University Of Utah Research Foundation |
Enhanced brain function by gaba-ergic stimulation
|
BR0112519A
(pt)
|
2000-07-07 |
2004-03-30 |
Ortho Mcneil Pharm Inc |
Derivados anticonvulsivantes úteis para prevenir o desenvolvimento de diabetes melito do tipo ii e sìndrome x
|
US6191117B1
(en)
|
2000-07-10 |
2001-02-20 |
Walter E. Kozachuk |
Methods of producing weight loss and treatment of obesity
|
US6946243B2
(en)
|
2000-07-20 |
2005-09-20 |
Solvay Pharmaceuticals Gmbh |
Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
|
MXPA03001001A
(es)
|
2000-08-02 |
2003-10-14 |
Johnson & Johnson |
Derivados anticonvulsionantes utiles para el tratameinto de la depresion.
|
US6395783B1
(en)
|
2000-10-23 |
2002-05-28 |
Brookhaven Science Associates, Llc |
Treatment of PCP addiction and PCP addiction-related behavior
|
PT1333887E
(pt)
|
2000-10-30 |
2006-10-31 |
Ortho Mcneil Pharm Inc |
Metodo de tratamento de desordens musculares
|
US20050136106A1
(en)
|
2000-11-20 |
2005-06-23 |
Adrian Sandler |
Therapeutic placebo enhancement of commonly used medications
|
SK6092003A3
(en)
|
2000-11-30 |
2004-07-07 |
Pfizer Prod Inc |
Combination of GABA agonists and aldosereductase inhibitors
|
CA2430298A1
(en)
|
2000-11-30 |
2002-06-06 |
Banavara Lakshman Mylari |
Combination of gaba agonists and sorbitol dehydrogenase inhibitors
|
NZ548578A
(en)
|
2001-02-02 |
2008-03-28 |
Ortho Mcneil Pharm Inc |
Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
|
US6936590B2
(en)
|
2001-03-13 |
2005-08-30 |
Bristol Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
US20060198815A1
(en)
|
2001-03-19 |
2006-09-07 |
Praecis Pharmaceuticals, Inc. |
Pharmaceutical formulations for sustained release
|
AU2002250203B2
(en)
|
2001-03-28 |
2006-08-10 |
Biogen Ma Inc. |
Use of neublastin polypeptides for treating neuropathic pain
|
US20070026440A1
(en)
|
2001-04-06 |
2007-02-01 |
Broderick Patricia A |
Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors, and brain and spinal cord injuries using electrodes with microvoltammetry
|
US8012506B2
(en)
|
2001-04-10 |
2011-09-06 |
Pernix Therapeutics, Llc |
Tannate compositions, methods of making and methods of use
|
US8257746B2
(en)
|
2001-04-10 |
2012-09-04 |
Pernix Therapeutics, Llc |
Tannate compositions, methods of making and methods of use
|
ES2258141T3
(es)
|
2001-04-11 |
2006-08-16 |
Bristol-Myers Squibb Company |
Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
|
US6573287B2
(en)
|
2001-04-12 |
2003-06-03 |
Bristo-Myers Squibb Company |
2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
|
CA2445528A1
(en)
|
2001-04-26 |
2002-11-07 |
Ortho-Mcneil Pharmaceutical, Inc. |
Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
|
US20020187996A1
(en)
|
2001-05-14 |
2002-12-12 |
Dewey Stephen L. |
Prevention of addiction in pain management
|
US6462084B1
(en)
|
2001-05-14 |
2002-10-08 |
Brookhaven Science Associates, Llc |
Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
|
US7766013B2
(en)
|
2001-06-05 |
2010-08-03 |
Alexza Pharmaceuticals, Inc. |
Aerosol generating method and device
|
US6967212B2
(en)
|
2001-05-30 |
2005-11-22 |
Bristol-Myers Squibb Company |
Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
|
US7105556B2
(en)
|
2001-05-30 |
2006-09-12 |
Bristol-Myers Squibb Company |
Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
|
DE10127134A1
(de)
|
2001-06-05 |
2002-12-12 |
Roehm Gmbh |
verfahren zur Herstellung von Formkörpern aus (Meth)acrylat-Copolymeren mittels Spritzguß
|
GB0113663D0
(en)
|
2001-06-05 |
2001-07-25 |
Novartis Ag |
Use of organic compounds
|
US7041650B2
(en)
|
2001-07-09 |
2006-05-09 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivative salts
|
US20030139332A1
(en)
|
2001-07-09 |
2003-07-24 |
The Regents Of The University Of California |
Use of matrix metalloproteinase inhibitors to mitigate nerve damage
|
UA78211C2
(en)
|
2001-07-09 |
2007-03-15 |
Ortho Mcneil Pharm Inc |
Salts of fructopyranose derivatives as anticonvulsant
|
EP2159723A1
(en)
|
2001-07-11 |
2010-03-03 |
CNS Response, Inc. |
Method for remote diagnosis and treatment using electroencephalografy
|
US20030032661A1
(en)
|
2001-08-02 |
2003-02-13 |
Boehringer Ingelheim Pharma Kg |
Pramipexole as an anticonvulsant
|
WO2003011271A2
(en)
|
2001-08-03 |
2003-02-13 |
Children's Medical Center Corporation |
Methods and compositions for modulating brain damage
|
US20060173064A1
(en)
|
2001-08-24 |
2006-08-03 |
Lippa Arnold S |
(-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
|
EP1423127A1
(en)
|
2001-08-30 |
2004-06-02 |
Ortho-Mcneil Pharmaceutical, Inc. |
Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
|
WO2003020737A1
(en)
|
2001-09-05 |
2003-03-13 |
Bristol-Myers Squibb Company |
O-pyrazole glucoside sglt2 inhibitors and method of use
|
US20030092759A1
(en)
|
2001-09-24 |
2003-05-15 |
Abuzzahab Faruk S. |
Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
|
US20030072802A1
(en)
|
2001-10-11 |
2003-04-17 |
R.T. Alamo Ventures, Inc. |
Sustained release topiramate
|
US20030091630A1
(en)
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
DE10153078A1
(de)
|
2001-10-30 |
2003-05-22 |
Degussa |
Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
|
EP1442028A4
(en)
|
2001-11-06 |
2009-11-04 |
Bristol Myers Squibb Co |
SUBSTITUTED ACID DERIVATIVES, WHICH APPRECIATE AS ANTIDIBILICS AND AGENTS AGAINST OBESITAS, AND METHODS
|
US8329217B2
(en)
*
|
2001-11-06 |
2012-12-11 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Dual controlled release dosage form
|
CA2465952A1
(en)
|
2001-11-06 |
2003-05-15 |
Ortho-Mcneil Pharmaceutical, Inc. |
Treatment and prevention of paresthesia comprising co-therapy with anticonvulsant derivatives and potassium
|
MXPA04004572A
(es)
|
2001-11-14 |
2005-07-05 |
Ralph Ryback |
Metodo para el tratamiento de enfermedades autoinmunes.
|
US6831102B2
(en)
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
US20070167853A1
(en)
|
2002-01-22 |
2007-07-19 |
Melker Richard J |
System and method for monitoring health using exhaled breath
|
EP1336602A1
(en)
|
2002-02-13 |
2003-08-20 |
Giovanni Scaramuzzino |
Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
|
US7927613B2
(en)
|
2002-02-15 |
2011-04-19 |
University Of South Florida |
Pharmaceutical co-crystal compositions
|
WO2004078163A2
(en)
|
2003-02-28 |
2004-09-16 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
US7446107B2
(en)
|
2002-02-15 |
2008-11-04 |
Transform Pharmaceuticals, Inc. |
Crystalline forms of conazoles and methods of making and using the same
|
US6559293B1
(en)
|
2002-02-15 |
2003-05-06 |
Transform Pharmaceuticals, Inc. |
Topiramate sodium trihydrate
|
US7659082B2
(en)
|
2002-02-19 |
2010-02-09 |
Xenon Pharmaceuticals Inc. |
Methods for identifying analgesic agents
|
US20030225002A1
(en)
|
2002-02-26 |
2003-12-04 |
Livingstone Ian R. |
Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents
|
US20030162695A1
(en)
|
2002-02-27 |
2003-08-28 |
Schatzberg Alan F. |
Glucocorticoid blocking agents for increasing blood-brain barrier permeability
|
CA2478183C
(en)
|
2002-03-12 |
2010-02-16 |
Merck & Co. Inc. |
Substituted amides
|
PL223471B1
(pl)
|
2002-03-15 |
2016-10-31 |
Cypress Bioscience Inc |
Kompozycja farmaceutyczna zawierająca milnacypran do stosowania w leczeniu zespołu nadwrażliwości jelita grubego
|
WO2003080072A1
(en)
|
2002-03-18 |
2003-10-02 |
Cady Roger K |
Preemptive prophylaxis of migraine
|
WO2003082207A2
(en)
|
2002-03-29 |
2003-10-09 |
Alza Corporation |
Volume efficient controlled release dosage form
|
AU2003225102A1
(en)
|
2002-04-23 |
2003-11-10 |
Bristol-Myers Squibb Company |
Modified-release vasopeptidase inhibitor formulation, combinations and method
|
WO2004000280A1
(en)
|
2002-04-29 |
2003-12-31 |
Shire Laboraties, Inc. |
Pharmaceutical formulations with improved bioavailability
|
US7060725B2
(en)
|
2002-05-13 |
2006-06-13 |
Janssen Pharmaceutica N.V. |
Substituted sulfamate anticonvulsant derivatives
|
US20040014681A1
(en)
|
2002-05-14 |
2004-01-22 |
Ralph Ryback |
Method for treating dermatoses and tissue damage
|
CA2483464C
(en)
|
2002-05-17 |
2011-12-20 |
Duke University |
Method for treating obesity
|
US7057046B2
(en)
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
EP1364649A1
(en)
|
2002-05-23 |
2003-11-26 |
Cilag AG |
Adduct of topiramate and tramadol hydrochioride and uses thereof
|
US20040063751A1
(en)
|
2002-05-31 |
2004-04-01 |
Pharmacia Corporation |
Combination therapy for the treatment of amyotrophic lateral sclerosis (ALS) with cyclooxygenase-2 (COX-2) inhibitor(s) and a second drug
|
AU2003243354A1
(en)
|
2002-05-31 |
2003-12-19 |
Transform Pharmaceuticals, Inc. |
Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
|
US20030235576A1
(en)
|
2002-06-15 |
2003-12-25 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New drug combinations for the treatment of ischaemic conditions
|
US20070243254A1
(en)
|
2002-06-26 |
2007-10-18 |
David Edgren |
Novel drug compositions and dosage forms of topiramate
|
AR039744A1
(es)
|
2002-06-26 |
2005-03-09 |
Alza Corp |
Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
|
US20040087513A1
(en)
|
2002-07-04 |
2004-05-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New drug combinations based on sodium channel blockers and magnesium salts
|
BR0312503A
(pt)
|
2002-07-09 |
2007-06-26 |
Bristol Myers Squibb Co |
derivados heterocìclicos substituìdos úteis como agentes antidiabéticos e antiobesidade, composição farmacêutica, uso e combinação dos mesmos
|
JP4579681B2
(ja)
|
2002-07-09 |
2010-11-10 |
ブリストル−マイヤーズ スクイブ カンパニー |
抗糖尿病薬および抗肥満薬として有用な置換ヘテロシクロ誘導体および方法
|
PL375442A1
(en)
|
2002-07-18 |
2005-11-28 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
AU2003253925A1
(en)
|
2002-07-18 |
2004-02-09 |
Banyu Pharmaceutical Co., Ltd. |
Combination therapy for the treatment of obesity
|
WO2004010970A1
(en)
|
2002-07-29 |
2004-02-05 |
Alza Corporation |
Formulations and dosage forms for controlled delivery of topiramate
|
DE60332743D1
(de)
|
2002-08-08 |
2010-07-08 |
Kissei Pharmaceutical |
Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung
|
JP2004137245A
(ja)
|
2002-08-23 |
2004-05-13 |
Kissei Pharmaceut Co Ltd |
ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
|
DE50213170D1
(de)
|
2002-09-04 |
2009-02-12 |
Fraunhofer Ges Forschung |
Verwendung eines Mittel zur Therapie der Herzhypertrophie
|
EP1539135B1
(en)
|
2002-09-17 |
2007-04-25 |
Motac Neuroscience Limited |
Treatment of dyskinesia
|
AU2003218462A1
(en)
|
2002-10-01 |
2004-04-23 |
Merck And Co., Inc. |
Treatment of obesity and other disorders associated with excessive food intake
|
WO2004037181A2
(en)
|
2002-10-23 |
2004-05-06 |
Bristol-Myers Squibb Company |
Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
|
US20040082543A1
(en)
|
2002-10-29 |
2004-04-29 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
|
US7196209B2
(en)
|
2002-10-31 |
2007-03-27 |
Ortho-Mcneil Pharmaceutical, Inc. |
Continuous process for the preparation of fructopyranose sulfamate derivatives
|
US7098235B2
(en)
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
US7208477B2
(en)
|
2002-12-02 |
2007-04-24 |
University Of Florida Research Foundation, Inc. |
Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
|
US20040122033A1
(en)
|
2002-12-10 |
2004-06-24 |
Nargund Ravi P. |
Combination therapy for the treatment of obesity
|
PL377351A1
(pl)
*
|
2002-12-13 |
2006-01-23 |
Cilag Ag |
Preparaty o kontrolowanym uwalnianiu zawierające tramadol i topiramat
|
KR20050096915A
(ko)
*
|
2002-12-13 |
2005-10-06 |
시락 아게 |
안정한 토피라메이트 제제
|
ITMI20022658A1
(it)
|
2002-12-17 |
2004-06-18 |
Nicox Sa |
Farmaci per il dolore cronico.
|
AU2003299983A1
(en)
|
2002-12-20 |
2004-07-22 |
St. James Associates Llc/Faber Research Series |
High pressure compaction for pharmaceutical formulations
|
CA2510319A1
(en)
|
2002-12-20 |
2004-07-15 |
Thomas J. Smith |
High pressure compaction for pharmaceutical formulations
|
JP4469846B2
(ja)
|
2003-01-31 |
2010-06-02 |
エラン ファーマ インターナショナル,リミティド |
ナノ粒子状トピラメート製剤
|
ATE550022T1
(de)
|
2003-02-28 |
2012-04-15 |
Mcneil Ppc Inc |
Pharmazeutische mischkristalle von celecoxib- nicotinamid
|
US20040204472A1
(en)
|
2003-03-04 |
2004-10-14 |
Pharmacia Corporation |
Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
|
UA81657C2
(ru)
|
2003-03-04 |
2008-01-25 |
Орто-Макнейл Фармасьютикел, Инк. |
Способ получения противосудорожных производных топирамата
|
WO2004089965A2
(en)
|
2003-04-07 |
2004-10-21 |
Cipla Ltd |
Topiramate and processes for the preparation thereof
|
SI1477166T1
(sl)
|
2003-04-28 |
2006-12-31 |
Biofrontera Bioscience Gmbh |
Uporaba riluzola, kombiniranega s primernimi pomoznimi in dodatnimi snovmi, za zdravljenje bolezni,za katere je znacilna hiperproliferacija keratinocitov, se zlasti nevrodermitisa in psoriaze
|
US20040229943A1
(en)
|
2003-05-16 |
2004-11-18 |
Cephalon Inc |
Analeptic and drug combinations
|
EP2601953A1
(en)
|
2003-05-23 |
2013-06-12 |
Otsuka Pharmaceutical Co., Ltd. |
Carbostyril derivatives and mood stabilizers for treating mood disorders
|
WO2004105699A2
(en)
|
2003-05-28 |
2004-12-09 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
|
US20060160834A1
(en)
|
2003-06-06 |
2006-07-20 |
Fong Tung M |
Combination therapy for the treatment of hypertension
|
US20070099884A1
(en)
|
2003-06-06 |
2007-05-03 |
Erondu Ngozi E |
Combination therapy for the treatment of diabetes
|
US20060148721A1
(en)
|
2003-06-06 |
2006-07-06 |
Erondu Ngozi E |
Combination therapy for the treatment of dyslipidemia
|
WO2005000294A1
(en)
|
2003-06-06 |
2005-01-06 |
Pharmacia Corporation |
Selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
|
US7459474B2
(en)
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
US7235662B2
(en)
|
2003-06-11 |
2007-06-26 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
NZ544119A
(en)
*
|
2003-06-25 |
2008-04-30 |
Novartis Ag |
Tablet comprising fluvastatin and carmellose calcium
|
US6949518B1
(en)
|
2003-06-25 |
2005-09-27 |
Pao-Hsien Chu |
Methods for treating macular degeneration with topiramate
|
JP4705911B2
(ja)
|
2003-06-26 |
2011-06-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
ベンゾジアゼピンcgrp受容体拮抗物質
|
US7476665B2
(en)
|
2003-06-26 |
2009-01-13 |
Merck & Co., Inc. |
Benzodiazepine CGRP receptor antagonists
|
US20070111204A1
(en)
|
2003-06-27 |
2007-05-17 |
Kathleen Delgrosso |
Methods for detecting nucleic acid variations
|
WO2005007628A1
(en)
|
2003-07-11 |
2005-01-27 |
Bristol-Myers Squibb Company |
Tetrahydroquinoline derivatives as cannabinoid receptor modulators
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
CA2534920A1
(en)
|
2003-08-06 |
2005-02-24 |
Alza Corporation |
Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
|
US20050031544A1
(en)
|
2003-08-07 |
2005-02-10 |
Njemanze Philip Chidi |
Receptor mediated nanoscale copolymer assemblies for diagnostic imaging and therapeutic management of hyperlipidemia and infectious diseases
|
US20050136108A1
(en)
|
2003-08-22 |
2005-06-23 |
Yam Noymi V. |
Stepwise delivery of topiramate over prolonged period of time
|
EP1673064A1
(en)
|
2003-08-28 |
2006-06-28 |
Sandoz AG |
Pharmaceutical composition comprising anticonvulsant with taste mask coating
|
AU2004268661A1
(en)
|
2003-09-02 |
2005-03-10 |
Alza Corporation |
Novel drug compositions and dosage forms of topiramate
|
US7611728B2
(en)
|
2003-09-05 |
2009-11-03 |
Supernus Pharmaceuticals, Inc. |
Osmotic delivery of therapeutic compounds by solubility enhancement
|
US7371759B2
(en)
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
WO2005048979A2
(en)
|
2003-10-06 |
2005-06-02 |
Torrent Pharmaceuticals Limited |
Pharmaceutical composition having casing with multiple micro tablets
|
US7425410B2
(en)
|
2003-10-30 |
2008-09-16 |
Free State Diagnostics, Llc |
Methods for diagnosing a bipolar disorder and unipolar disorder
|
WO2005048990A2
(en)
|
2003-11-13 |
2005-06-02 |
Alza Corporation |
Melt blend dispersions comprising a low water solubility drug and an ethylene oxide-propylene oxide block copolymer
|
MXPA06005462A
(es)
|
2003-11-14 |
2006-12-15 |
Johnson & Johnson |
Liberacion controlada de topiramato en formas de dosificacion liquida.
|
WO2005049043A1
(en)
|
2003-11-18 |
2005-06-02 |
Ortho-Mcneil Pharmaceutical, Inc. |
Combination therapy comprising metformin and anticonvulsant agents
|
US20050181049A1
(en)
|
2003-11-19 |
2005-08-18 |
Dong Liang C. |
Composition and method for enhancing bioavailability
|
US7420059B2
(en)
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
WO2005063248A1
(en)
|
2003-12-22 |
2005-07-14 |
Sepracor Inc. |
Modafinil combination therapy for improving sleep quality
|
CA2550866A1
(en)
|
2003-12-23 |
2005-07-14 |
Alza Corporation |
Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
|
AU2004308962A1
(en)
|
2003-12-24 |
2005-07-14 |
Sepracor Inc. |
Melatonin combination therapy for improving sleep quality
|
US20050175696A1
(en)
*
|
2003-12-29 |
2005-08-11 |
David Edgren |
Drug granule coatings that impart smear resistance during mechanical compression
|
JP2007517063A
(ja)
|
2003-12-29 |
2007-06-28 |
アルザ・コーポレーシヨン |
トピラメートの新規な薬剤組成物および剤形
|
US7713959B2
(en)
|
2004-01-13 |
2010-05-11 |
Duke University |
Compositions of an anticonvulsant and mirtazapine to prevent weight gain
|
JP2007517901A
(ja)
|
2004-01-13 |
2007-07-05 |
デューク・ユニバーシティー |
体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
|
US7273881B2
(en)
|
2004-01-16 |
2007-09-25 |
Bristol-Myers Squibb Company |
Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
US7326728B2
(en)
|
2004-01-16 |
2008-02-05 |
Bristol-Myers Squibb Company |
Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof
|
US7569689B2
(en)
|
2004-01-16 |
2009-08-04 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
US7625921B2
(en)
|
2004-01-16 |
2009-12-01 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
US7253283B2
(en)
|
2004-01-16 |
2007-08-07 |
Bristol-Myers Squibb Company |
Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
US7605264B2
(en)
|
2004-01-16 |
2009-10-20 |
Bristol-Myers Squibb Company |
Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
WO2005082372A1
(en)
|
2004-01-29 |
2005-09-09 |
Pfizer Products Inc. |
COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
|
US20050182105A1
(en)
|
2004-02-04 |
2005-08-18 |
Nirschl Alexandra A. |
Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
|
US7820702B2
(en)
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
WO2005079773A2
(en)
|
2004-02-13 |
2005-09-01 |
Neuromolecular, Inc. |
Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
|
ES2241478B1
(es)
|
2004-02-13 |
2006-11-16 |
Lacer S.A. |
Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo.
|
US20050181071A1
(en)
|
2004-02-18 |
2005-08-18 |
Binder Michael R. |
Method for the treatment of clinical depression
|
CA2557766C
(en)
|
2004-03-04 |
2013-02-05 |
Kissei Pharmaceutical Co., Ltd. |
Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
|
ZA200606792B
(en)
|
2004-03-04 |
2007-12-27 |
Kissei Pharmaceutical |
Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
|
US8058245B2
(en)
|
2004-03-04 |
2011-11-15 |
Kissei Pharmaceutical Co., Ltd. |
Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
|
US20050203287A1
(en)
|
2004-03-11 |
2005-09-15 |
Chandrasekhar Batchu |
Process for the preparation of sulfamate derivatives
|
TWI349666B
(en)
|
2004-03-12 |
2011-10-01 |
Lundbeck & Co As H |
Substituted morpholine and thiomorpholine derivatives
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
AU2005228868B2
(en)
|
2004-03-24 |
2012-02-09 |
Janssen Pharmaceutica, N.V. |
Tetrahydro-indazole cannabinoid modulators
|
US7354925B2
(en)
|
2004-03-29 |
2008-04-08 |
Pfizer Inc. |
Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists
|
US20070185197A1
(en)
|
2004-03-31 |
2007-08-09 |
Hideki Fujikura |
Phenol derivative, medicinal composition containing the same, and medicinal use thereof
|
US20050222209A1
(en)
|
2004-04-01 |
2005-10-06 |
Zeldis Jerome B |
Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
|
GB0408308D0
(en)
|
2004-04-14 |
2004-05-19 |
Vectura Ltd |
Pharmaceutical compositions
|
JP2007536229A
(ja)
|
2004-05-03 |
2007-12-13 |
デューク・ユニバーシティー |
体重減少に作用するための組成物
|
US20050250838A1
(en)
*
|
2004-05-04 |
2005-11-10 |
Challapalli Prasad V |
Formulation for sustained delivery
|
WO2005113506A1
(en)
|
2004-05-14 |
2005-12-01 |
Irm Llc |
Compounds and compositions as ppar modulators
|
WO2005113519A1
(en)
|
2004-05-14 |
2005-12-01 |
Irm Llc |
Compounds and compositions as ppar modulators
|
PE20060362A1
(es)
|
2004-05-24 |
2006-05-15 |
Irm Llc |
Compuestos de oxazol como moduladores de ppar
|
WO2005120523A1
(en)
|
2004-06-04 |
2005-12-22 |
Mood Management Sciences, Llc |
Methods and compositions for treating mood disorder
|
US20070212428A1
(en)
|
2004-06-04 |
2007-09-13 |
Mood Management Sciences, Inc. |
Methods and compositions for treating mood disorder
|
WO2006007323A2
(en)
|
2004-06-28 |
2006-01-19 |
Alza Corporation |
Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
WO2006014484A2
(en)
|
2004-07-02 |
2006-02-09 |
Surmodics, Inc. |
Methods and devices for the treatment of ocular conditions
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
US7829279B1
(en)
|
2004-07-16 |
2010-11-09 |
The Regents Of The University Of California |
Compositions and methods for diagnosis and treatment of epilepsy
|
CN1988889A
(zh)
|
2004-07-22 |
2007-06-27 |
株式会社太平洋 |
含托吡酯的缓释制剂及其制备方法
|
ATE553757T1
(de)
|
2004-08-02 |
2012-05-15 |
John W Olney |
Verhinderung von pathologischen anstiegen der nervenzellsuizidrate in unreifen nervensystemen
|
JP2008509144A
(ja)
|
2004-08-04 |
2008-03-27 |
アルザ・コーポレーシヨン |
上昇するゼロ次放出パターンを示す持続薬剤放出組成物、そのような組成物を製造する方法
|
WO2006015930A1
(en)
|
2004-08-10 |
2006-02-16 |
Nicox S.A. |
Phenol derivatives
|
EP1784390A2
(en)
|
2004-08-13 |
2007-05-16 |
Amgen Inc. |
Substituted benzofused heterocycles
|
PT1627881E
(pt)
|
2004-08-19 |
2006-12-29 |
Helm Ag |
Processo para a preparação de topiramato
|
US20060039866A1
(en)
|
2004-08-20 |
2006-02-23 |
Cypress Bioscience, Inc. |
Method for treating sleep-related breathing disorders
|
CN101014345A
(zh)
|
2004-09-09 |
2007-08-08 |
默克公司 |
三环酰苯胺螺环内酰胺cgrp受体拮抗剂
|
US7750010B2
(en)
|
2004-09-13 |
2010-07-06 |
Merck Sharp & Dohme Corp. |
Tricyclic anilide spirohydantion CGRP receptor antagonists
|
JP2008512481A
(ja)
|
2004-09-13 |
2008-04-24 |
メルク エンド カムパニー インコーポレーテッド |
二環式アニリドスピロラクタムcgrp受容体拮抗薬
|
WO2006032042A2
(en)
|
2004-09-15 |
2006-03-23 |
Regeneron Pharmaceuticals, Inc. |
Us of cntf or a cntf derivative in combination with a further compound for the preparation of medicament for the treatment of obesity
|
AR051446A1
(es)
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
CA2577821A1
(en)
|
2004-09-24 |
2006-04-06 |
Merck & Co., Inc. |
Combination therapy for the treatment of obesity
|
EA200700871A1
(ru)
|
2004-10-15 |
2007-10-26 |
Янссен Фармацевтика Н. В. |
Способы нейропротекции
|
US8779175B2
(en)
|
2004-10-25 |
2014-07-15 |
Synthonics, Inc. |
Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
|
US20060088886A1
(en)
|
2004-10-25 |
2006-04-27 |
Anlong Ouyang |
Topiramate analogs
|
US7638291B2
(en)
|
2004-10-25 |
2009-12-29 |
Seradyn, Inc. |
Immunoassays for topiramate
|
WO2006049933A2
(en)
|
2004-10-29 |
2006-05-11 |
Merck & Co., Inc. |
Compositions and methods for the treatment of obesity and sexual dysfunction
|
EP1817023A4
(en)
|
2004-11-16 |
2010-08-18 |
Limerick Biopharma Inc |
METHOD AND COMPOSITIONS FOR PAIN TREATMENT
|
US20060121112A1
(en)
|
2004-12-08 |
2006-06-08 |
Elan Corporation, Plc |
Topiramate pharmaceutical composition
|
AU2005314021B2
(en)
*
|
2004-12-09 |
2010-02-11 |
Insys Therapeutics, Inc. |
Room-temperature stable dronabinol formulations
|
US20060129324A1
(en)
|
2004-12-15 |
2006-06-15 |
Biogenesys, Inc. |
Use of quantitative EEG (QEEG) alone and/or other imaging technology and/or
in combination with genomics and/or proteomics and/or biochemical analysis and/or other diagnostic modalities, and CART and/or AI and/or statistical and/or other mathematical analysis methods for improved medical and other diagnosis, psychiatric and other disease treatment, and also for veracity verification and/or lie detection applications.
|
GB0428170D0
(en)
|
2004-12-23 |
2005-01-26 |
Biopartners Ltd |
Mono and Combination Therapy
|
US8067217B2
(en)
*
|
2004-12-28 |
2011-11-29 |
Kaneka Corporation |
Method for preserving reduced coenzyme Q10
|
US7589088B2
(en)
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7361654B2
(en)
|
2005-01-13 |
2008-04-22 |
Bristol-Myers Squibb Co. |
Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
US7411071B2
(en)
|
2005-01-13 |
2008-08-12 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
US7317024B2
(en)
|
2005-01-13 |
2008-01-08 |
Bristol-Myers Squibb Co. |
Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
WO2006076796A1
(en)
|
2005-01-19 |
2006-07-27 |
Merck Frosst Canada Ltd. |
Cathepsin k inhibitors and obesity
|
WO2006077492A1
(en)
*
|
2005-01-24 |
2006-07-27 |
Ranbaxy Laboratories Limited |
Sustained release oral dosage forms of gabapentin
|
CN101111245A
(zh)
|
2005-01-27 |
2008-01-23 |
阿雷姆贝克有限公司 |
左乙拉西坦延长释放制剂
|
JP2008528700A
(ja)
|
2005-02-03 |
2008-07-31 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
Pparモジュレーターとしての化合物および組成物
|
WO2006082245A1
(en)
|
2005-02-07 |
2006-08-10 |
Novo Nordisk A/S |
Pharmaceutical preparations comprising insulin, zinc ions and a zinc-binding ligand
|
KR100822519B1
(ko)
|
2005-02-15 |
2008-04-16 |
주식회사종근당 |
위장 내에서 제어방출되는 단일 매트릭스 정제
|
AU2006219643A1
(en)
|
2005-03-01 |
2006-09-08 |
Pfizer Limited |
Use of PDE7 inhibitors for the treatment of neuropathic pain
|
WO2006096439A2
(en)
|
2005-03-04 |
2006-09-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
|
IS7748A
(is)
|
2005-03-17 |
2006-09-18 |
Actavis Group |
Samsetning fyrir töflur sem innihalda topiramate
|
US20060211632A1
(en)
|
2005-03-17 |
2006-09-21 |
Bachmann Kenneth A |
PXR agonists for cardiovascular disease
|
AU2005215928A1
(en)
|
2005-03-18 |
2006-10-05 |
Ucl Biomedica Plc |
Genetic predictor for clinical use of drugs used in the treatment of neurological conditions
|
US20080009538A1
(en)
|
2005-03-21 |
2008-01-10 |
Phil Skolnick |
Methods and compositions for the treatment of urinary incontinence
|
MX2007012157A
(es)
|
2005-04-01 |
2008-03-14 |
Intezyne Technologies Llc |
Micelas polimericas para suministro de farmacos.
|
WO2006113095A2
(en)
|
2005-04-12 |
2006-10-26 |
Free State Diagnostics, Llc |
Methods for diagnosing a bipolar disorder and attention-deficit/hyperactivity disorder
|
PL1883451T3
(pl)
|
2005-04-13 |
2011-05-31 |
Neuraxon Inc |
Podstawione związki indolowe mające aktywność hamowania NOS
|
US20110117070A1
(en)
|
2005-04-19 |
2011-05-19 |
Aurora Sheena K |
Compositions and methods for treating headache
|
EP2380573B1
(en)
|
2005-05-06 |
2015-02-25 |
Bial-Portela & CA, S.A. |
Eslicarbazepine acetate and methods of use
|
US20060252745A1
(en)
|
2005-05-06 |
2006-11-09 |
Almeida Jose L D |
Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
AU2006277684A1
(en)
|
2005-05-18 |
2007-02-15 |
Neuraxon, Inc. |
Substituted benzimidazole compounds with dual NOS inhibitory activity and muopioid agonist activity
|
EP1901733B1
(en)
|
2005-05-23 |
2016-04-06 |
President and Fellows of Harvard College |
Huperzine for use in the treatment of neuropathic pain
|
CN101208092A
(zh)
|
2005-05-31 |
2008-06-25 |
奥雷西根治疗公司 |
用于处理精神障碍的方法和组合物
|
KR20080021082A
(ko)
|
2005-06-20 |
2008-03-06 |
쉐링 코포레이션 |
히스타민 h3 길항제로서 유용한 피페리딘 유도체
|
ES2337728T3
(es)
|
2005-06-20 |
2010-04-28 |
Schering Corporation |
Piperidinas sustituidas unidas a carbono y sus derivados utiles como antagonistas de histamina h3.
|
WO2007001939A1
(en)
|
2005-06-27 |
2007-01-04 |
Janssen Pharmaceutica N.V. |
Tetrahydro-pyranopyrazole compounds displaying cannabinoid modulating activities
|
WO2007002872A2
(en)
|
2005-06-29 |
2007-01-04 |
Alza Corporation |
Semi-permeable compositions providing reduced drying time for osmotic dosage forms
|
US20070021500A1
(en)
|
2005-07-12 |
2007-01-25 |
Twyman Roy E |
Methods for neuroprotection
|
US20070021501A1
(en)
|
2005-07-12 |
2007-01-25 |
Twyman Roy E |
Methods of treating epileptogenesis
|
CN101237886A
(zh)
|
2005-07-27 |
2008-08-06 |
奥雷西根治疗公司 |
产生重量减轻的组合物
|
PL1912650T3
(pl)
|
2005-08-03 |
2018-01-31 |
Sprout Pharmaceuticals Inc |
Zastosowanie flibanseryny w leczeniu otyłości
|
WO2007026224A2
(en)
|
2005-08-31 |
2007-03-08 |
Pfizer Products Inc. |
5-ht1b antagonist composition for depression, anxiety and cognition
|
US7514068B2
(en)
|
2005-09-14 |
2009-04-07 |
Concert Pharmaceuticals Inc. |
Biphenyl-pyrazolecarboxamide compounds
|
US20070276001A1
(en)
|
2005-09-14 |
2007-11-29 |
Concert Pharmaceuticals Inc. |
Biphenyl-pyrazolecarboxamide compounds
|
KR20080059208A
(ko)
|
2005-09-16 |
2008-06-26 |
세레우사이언스 아베 |
수면 호흡 장애를 예방 및 치료하는 방법과 그 수단
|
MX2008003691A
(es)
|
2005-09-16 |
2009-02-27 |
Janssen Pharmaceutica Nv |
Ciclopropil aminas como moduladores del receptor de histamina h3.
|
US7332604B2
(en)
|
2005-09-20 |
2008-02-19 |
Schering Corporation |
1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine
|
US8378096B2
(en)
|
2005-09-23 |
2013-02-19 |
Janssen Pharmaceutica N.V. |
Hexahydro-cycloheptapyrazole cannabinoid modulators
|
US7825151B2
(en)
|
2005-09-23 |
2010-11-02 |
Janssen Pharmaceutica Nv |
Hexahydro-cyclooctyl pyrazole cannabinoid modulators
|
US8378117B2
(en)
|
2005-09-23 |
2013-02-19 |
Janssen Pharmaceutica N.V. |
Hexahydro-cycloheptapyrazole cannabinoid modulators
|
EP1937646A1
(en)
|
2005-09-23 |
2008-07-02 |
Janssen Pharmaceutica N.V. |
Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
|
CA2623535A1
(en)
|
2005-09-23 |
2007-04-19 |
Janssen Pharmaceutica N.V. |
Hexahydro cyclooctyl pyrazole cannabinoid modulators
|
WO2007038610A2
(en)
|
2005-09-26 |
2007-04-05 |
President & Fellows Of Harvard College |
Use of natural products for treatment of neurological disorders
|
CA2521272A1
(en)
|
2005-10-04 |
2007-04-04 |
Bernard Charles Sherman |
Capsules comprising topiramate
|
WO2007047351A2
(en)
|
2005-10-13 |
2007-04-26 |
Orexigen Therapeutics, Inc. |
Methods for treating hypertension in overweight and obese individuals
|
US7378434B2
(en)
|
2005-10-14 |
2008-05-27 |
Mutual Pharmaceutical Company, Inc. |
Metaxalone products, method of manufacture, and method of use
|
DE202005016250U1
(de)
|
2005-10-17 |
2006-01-26 |
Helm Ag |
Topiramat und pharmazeutische Formulierungen davon
|
BRPI0617621A2
(pt)
|
2005-10-21 |
2011-08-02 |
Novartis Ag |
combinação de compostos orgánicos
|
US7488725B2
(en)
|
2005-10-31 |
2009-02-10 |
Bristol-Myers Squibb Co. |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
|
RU2008122548A
(ru)
|
2005-11-07 |
2009-12-20 |
Айрм Ллк (Bm) |
Соединения и композиции, как модуляторы арпп (активированных рецепторов пролифератора пероксисом)
|
DE602006016323D1
(de)
|
2005-11-07 |
2010-09-30 |
Irm Llc |
Oxazol- und thiazol-verbindungen als ppar-modulatoren
|
CA2626446A1
(en)
|
2005-11-07 |
2007-05-18 |
Irm Llc |
Compounds and compositions as ppar modulators
|
BRPI0618918B8
(pt)
|
2005-11-22 |
2021-05-25 |
Nalpropion Pharmaceuticals Llc |
uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea
|
WO2007089318A2
(en)
|
2005-11-23 |
2007-08-09 |
Orexigen Therapeutics, Inc. |
Compositions and methods for reducing food cravings
|
WO2007075377A2
(en)
|
2005-12-15 |
2007-07-05 |
Cytokinetics, Inc. |
Certain chemical entities, compositions and methods
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
PE20071162A1
(es)
|
2005-12-21 |
2007-11-30 |
Schering Corp |
Combinacion de un antagonista/agonista inverso de h3 y un supresor del apetito
|
CA2634250A1
(en)
|
2005-12-21 |
2007-07-05 |
Schering Corporation |
Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
|
US7879880B2
(en)
|
2005-12-21 |
2011-02-01 |
Schering Corporation |
Substituted aniline derivatives useful as histamine H3 antagonists
|
US7824694B2
(en)
|
2006-01-12 |
2010-11-02 |
Allergan, Inc. |
Methods for enhancing therapeutic effects of a neurotoxin
|
WO2007084290A2
(en)
|
2006-01-12 |
2007-07-26 |
Orexigen Therapeutics, Inc. |
Compositions of an anticonvulsant and psychotherapeutic and methods of using the same for reversing weight gain
|
PE20070854A1
(es)
|
2006-01-20 |
2007-09-10 |
Schering Corp |
Compuestos heterociclos como agonistas del receptor de acido nicotinico
|
WO2007119178A2
(en)
|
2006-01-23 |
2007-10-25 |
Neuren Pharmaceuticals Limited |
Infusion pump
|
JP2009525280A
(ja)
|
2006-01-30 |
2009-07-09 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
Pparモジュレーターとしての化合物および組成物
|
JP2009525279A
(ja)
|
2006-01-30 |
2009-07-09 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
Pparモジュレーターとしてのスピロイミダゾール誘導体
|
RU2008135126A
(ru)
|
2006-01-30 |
2010-03-10 |
Айрм Ллк (Bm) |
Полициклические производные тетрагидроизохинолина и содержащие их композиции в качестве модуляторов ppar
|
US20070191371A1
(en)
|
2006-02-14 |
2007-08-16 |
Kalypsys, Inc. |
Heterocyclic modulators of ppar
|
EP3222142A1
(en)
|
2006-02-28 |
2017-09-27 |
Kodiak Sciences Inc. |
Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
|
WO2007099388A1
(en)
|
2006-03-01 |
2007-09-07 |
Glade Organics Private Limited |
An improved process for the manufacture of topiramate
|
WO2007106862A2
(en)
|
2006-03-14 |
2007-09-20 |
Kinemed, Inc. |
The use of statins to stimulate neurogenesis
|
WO2007108009A1
(en)
|
2006-03-17 |
2007-09-27 |
Alembic Limited |
A process for purification of topiramate
|
US20110263693A1
(en)
|
2006-03-31 |
2011-10-27 |
Dana-Farber Cancer Institute, Inc. |
Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
|
US20070232648A1
(en)
|
2006-03-31 |
2007-10-04 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
JP5457830B2
(ja)
*
|
2006-04-03 |
2014-04-02 |
オディディ,イサ |
オルガノゾル被膜を含む制御放出送達デバイス
|
DE102006015734A1
(de)
|
2006-04-04 |
2007-10-11 |
Hermann, Holger Lars, Dr. |
Kombinationspräparate aus Modafinil, Ritalin und Topiramat und deren Derivaten zur Behandlung von Kokainabhängigkeit und/oder Impulskontrollstörung
|
CN101420958A
(zh)
|
2006-04-06 |
2009-04-29 |
挪瓦卡尔迪阿公司 |
共投与腺苷a1受体拮抗剂和抗惊厥药
|
US7659281B2
(en)
|
2006-04-25 |
2010-02-09 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors
|
US8945623B2
(en)
|
2006-05-03 |
2015-02-03 |
Warsaw Orthopedic, Inc. |
Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use
|
US8840933B2
(en)
|
2006-05-03 |
2014-09-23 |
Warsaw Orthopedic, Inc. |
Method of treating neuronal injury by administering magnesium chloride and PEG
|
US8377994B2
(en)
|
2006-05-10 |
2013-02-19 |
Evonik Degussa GmeH |
Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
|
EP2026790A2
(en)
|
2006-05-19 |
2009-02-25 |
Janssen Pharmaceutica, N.V. |
Co-therapy for the treatment of epilepsy and related disorders
|
TW200812574A
(en)
|
2006-05-19 |
2008-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy for the treatment of epilepsy and related disorders
|
US7803778B2
(en)
|
2006-05-23 |
2010-09-28 |
Theracos, Inc. |
Glucose transport inhibitors and methods of use
|
WO2008010231A2
(en)
|
2006-05-26 |
2008-01-24 |
Alembic Limited |
A process for the purification of topiramate
|
CA2653940C
(en)
|
2006-05-30 |
2015-07-14 |
Janssen Pharmaceutica N.V. |
Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
|
US7479493B2
(en)
|
2006-06-29 |
2009-01-20 |
Janssen Pharmaceutica N.V. |
Substituted benzyl amine compounds
|
CN101511807A
(zh)
|
2006-06-29 |
2009-08-19 |
詹森药业有限公司 |
组胺h3受体的取代的苯甲酰胺调节剂
|
AU2007265239A1
(en)
|
2006-06-29 |
2008-01-03 |
Janssen Pharmaceutica N.V. |
Butyl and butynyl benzyl amine compounds
|
AU2007265240A1
(en)
|
2006-06-29 |
2008-01-03 |
Janssen Pharmaceutica N.V. |
Substituted aminomethyl benzamide compounds
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
US20080009534A1
(en)
|
2006-07-07 |
2008-01-10 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
|
US20080014252A1
(en)
|
2006-07-14 |
2008-01-17 |
Delprete Keith |
Topical compositions with long lasting effect
|
US9744137B2
(en)
|
2006-08-31 |
2017-08-29 |
Supernus Pharmaceuticals, Inc. |
Topiramate compositions and methods of enhancing its bioavailability
|
US20090239942A1
(en)
|
2006-09-15 |
2009-09-24 |
Cloyd James C |
Topiramate Compositions and Methods of Making and Using the Same
|
US20080078382A1
(en)
|
2006-09-20 |
2008-04-03 |
Lemahieu Edward |
Methods and Systems of Delivering Medication Via Inhalation
|
MX343867B
(es)
|
2006-11-09 |
2016-11-25 |
Orexigen Therapeutics Inc |
Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
|
ES2555066T3
(es)
|
2006-11-17 |
2015-12-28 |
Supernus Pharmaceuticals, Inc. |
Formulaciones de liberación sostenida de topiramato
|
CN102114002B
(zh)
|
2006-12-04 |
2016-05-11 |
苏佩努斯制药公司 |
托吡酯的增强的立即释放制剂
|
US20080153874A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan Inc. |
Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
|
CA2686816A1
(en)
|
2007-01-16 |
2008-07-24 |
The Johns Hopkins University |
Use of various glutamate receptor antagonists for delaying or preventing platelet activity or for treating or preventing a thrombotic disease or disorder
|
US20100197610A1
(en)
|
2007-01-23 |
2010-08-05 |
Baylor College Of Medicine |
Fructose 1, 6 bisphosphate - a novel anticonvulsant drug
|
WO2008089521A1
(en)
|
2007-01-25 |
2008-07-31 |
Verva Pharmaceuticals Ltd |
Insulin sensitisers and methods of treatment
|
WO2008091692A2
(en)
|
2007-01-25 |
2008-07-31 |
Joslin Diabetes Center, Inc. |
Methods of diagnosing, treating, and preventing increased vascular permeability
|
WO2008095086A2
(en)
|
2007-01-31 |
2008-08-07 |
University Of Virginia Patent Foundation |
Topiramate plus naltrexone for the treatment of addictive disorders
|
AU2007346591A1
(en)
|
2007-02-07 |
2008-08-14 |
Gosforth Centre (Holdings) Pty Ltd |
Treatment of ADHD
|
US7813811B2
(en)
|
2007-02-08 |
2010-10-12 |
Neuropace, Inc. |
Refillable reservoir lead systems
|
WO2008098195A2
(en)
|
2007-02-09 |
2008-08-14 |
Todd Maibach |
Film comprising nitroglycerin
|
WO2008097976A1
(en)
|
2007-02-09 |
2008-08-14 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
WO2008109343A1
(en)
|
2007-03-01 |
2008-09-12 |
Memory Pharmaceuticals Corporation |
Methods of treating bipolar disorder and memory and/or cognitive impairment associated therewith with (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate
|
WO2008106659A2
(en)
|
2007-03-01 |
2008-09-04 |
Memory Pharmaceuticals Corporation |
Methods of treating bipolar disorder and memory and/or cognitive impairment associated therewith
|
US20080226715A1
(en)
|
2007-03-16 |
2008-09-18 |
Albert Cha |
Therapeutic compositions and methods
|
US20080242684A1
(en)
|
2007-03-29 |
2008-10-02 |
Howard Dittrich |
Methods of administration of adenosine a1 receptor antagonists
|
AU2008232419B2
(en)
|
2007-04-02 |
2013-06-20 |
Theracos, Inc. |
Benzylic glycoside derivatives and methods of use
|
JP5548120B2
(ja)
|
2007-04-11 |
2014-07-16 |
オメロス コーポレーション |
嗜癖の予防および治療のための組成物および方法
|
US8198305B2
(en)
|
2007-04-13 |
2012-06-12 |
Concert Pharmaceuticals Inc. |
1,2-benzisoxazol-3-yl compounds
|
US8530463B2
(en)
|
2007-05-07 |
2013-09-10 |
Hale Biopharma Ventures Llc |
Multimodal particulate formulations
|
WO2008148064A1
(en)
|
2007-05-23 |
2008-12-04 |
Sunesis Pharmaceuticals, Inc. |
Weight loss treatment
|
WO2008148023A2
(en)
|
2007-05-23 |
2008-12-04 |
Medical College Of Georgia Research Institute, Inc. |
Compositions and methods for treating neurological disorders
|
US8071557B2
(en)
|
2007-06-13 |
2011-12-06 |
Vivus, Inc. |
Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
|
US20090004254A1
(en)
|
2007-06-19 |
2009-01-01 |
Todd Maibach |
Film comprising active drugs
|
US20120238554A1
(en)
*
|
2007-07-02 |
2012-09-20 |
Cowen Neil M |
Salts of potassium atp channel openers and uses thereof
|
MX2010000938A
(es)
|
2007-07-23 |
2010-07-01 |
Synosia Therapeutics Inc |
Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.
|
US20090030403A1
(en)
|
2007-07-27 |
2009-01-29 |
Leyde Kent W |
Methods and Systems for Attenuating the Tolerance Response to a Drug
|
WO2009018326A2
(en)
|
2007-07-31 |
2009-02-05 |
Limerick Biopharma, Inc. |
Soluble pyrone analogs methods and compositions
|
MX2010001141A
(es)
|
2007-07-31 |
2010-03-01 |
Limerick Biopharma Inc |
Analogos fosforiladosde pirona y metodos.
|
CA2696253A1
(en)
|
2007-08-08 |
2009-02-12 |
Janssen Pharmaceutica Nv |
Sulfamide derivative useful for the treatment of epilepsy
|
US7943653B2
(en)
|
2007-08-13 |
2011-05-17 |
Janssen Pharmaceutica N.V. |
Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
|
JP4809931B2
(ja)
|
2007-08-23 |
2011-11-09 |
セラコス・インコーポレイテッド |
ベンジルベンゼン誘導体およびその使用方法
|
WO2009026241A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
WO2009029308A1
(en)
|
2007-08-27 |
2009-03-05 |
University Of Virginia Patent Foundation |
Medication combinations for the treatment of alcoholism and drug addiction
|
US8318813B2
(en)
|
2007-09-13 |
2012-11-27 |
Lcs Group, Llc |
Method of treating binge eating disorder
|
SI2200588T1
(sl)
|
2007-09-25 |
2019-08-30 |
Solubest Ltd. |
Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
|
US20090087483A1
(en)
|
2007-09-27 |
2009-04-02 |
Sison Raymundo A |
Oral dosage combination pharmaceutical packaging
|
US8846053B2
(en)
|
2008-09-26 |
2014-09-30 |
Sdg, Inc. |
Orally bioavailable lipid-based constructs
|
US9145453B2
(en)
|
2007-09-28 |
2015-09-29 |
Sdg, Inc. |
Orally bioavailable lipid-based constructs
|
US20100285001A1
(en)
|
2007-10-02 |
2010-11-11 |
University Of Rochester |
Method and Compositions Related to Synergistic Responses to Oncogenic Mutations
|
US20120114670A1
(en)
|
2007-10-02 |
2012-05-10 |
University Of Rochester |
Methods and compositions related to synergistic responses to oncogenic mutations
|
US20120082659A1
(en)
|
2007-10-02 |
2012-04-05 |
Hartmut Land |
Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
|
WO2009054544A1
(en)
|
2007-10-26 |
2009-04-30 |
Eisai R & D Management Co., Ltd. |
Ampa receptor antagonists for parkinson's disease and movement disorders
|
JP2011506319A
(ja)
*
|
2007-12-06 |
2011-03-03 |
デュレクト コーポレーション |
疼痛、関節炎症状、または慢性疾患に伴う炎症の治療に有用な方法
|
WO2009073843A1
(en)
|
2007-12-06 |
2009-06-11 |
Cytotech Labs, Llc |
Inhalable compositions having enhanced bioavailability
|
CA2709905A1
(en)
*
|
2007-12-17 |
2009-06-25 |
Alfred Liang |
Abuse-resistant oxycodone composition
|
US20100317572A1
(en)
|
2007-12-20 |
2010-12-16 |
Neurosearch A/S |
Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound
|
JP5420568B2
(ja)
|
2008-01-17 |
2014-02-19 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
改良された抗TrkB抗体
|
BRPI0908425B8
(pt)
|
2008-02-28 |
2021-05-25 |
Univ Of Virgina Patent Foundation |
métodos para predizer uma predisposição para desenvolver alcoolismo, e para predizer uma resposta para o tratamento contra alcoolismo, e, uso de um antagonista do receptor de serotonina 5-ht3
|
WO2009126931A2
(en)
|
2008-04-11 |
2009-10-15 |
Xvasive, Inc. |
Combination therapy for bipolar disorder
|
WO2009131692A1
(en)
|
2008-04-23 |
2009-10-29 |
The Board Of Trustees Of The University Of Alabama |
Substrates for delivery of physiologically active agents
|
US20090270469A1
(en)
|
2008-04-25 |
2009-10-29 |
Auspex Pharmaceuticals, Inc. |
Substituted oxazolidinones
|
CA2722453C
(en)
|
2008-04-29 |
2018-03-20 |
Pharnext |
New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis
|
EA019571B1
(ru)
|
2008-04-29 |
2014-04-30 |
Фарнекст |
Применение сульфизоксазола для лечения болезни альцгеймера
|
EP3560496A1
(en)
|
2008-04-29 |
2019-10-30 |
Pharnext |
Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
|
US20090304789A1
(en)
|
2008-06-09 |
2009-12-10 |
Thomas Najarian |
Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
|
US8580298B2
(en)
|
2008-06-09 |
2013-11-12 |
Vivus, Inc. |
Low dose topiramate/phentermine composition and methods of use thereof
|
WO2010005507A1
(en)
|
2008-06-30 |
2010-01-14 |
Afgin Pharma, Llc |
Topical regional neuro-affective therapy
|
US20110212944A1
(en)
|
2008-07-01 |
2011-09-01 |
Julie Liu |
2-oxo-1-pyrrolidine derivatives
|
CA2946195A1
(en)
|
2008-07-17 |
2010-01-21 |
Micell Technologies, Inc. |
Drug delivery medical device
|
US9623000B2
(en)
|
2008-07-31 |
2017-04-18 |
Dekel Pharmaceuticals Ltd |
Compositions and methods for treating inflammatory disorders
|
EP2331088A4
(en)
|
2008-08-06 |
2011-10-12 |
Gosforth Ct Holdings Pty Ltd |
COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
|
US20100074973A1
(en)
|
2008-08-27 |
2010-03-25 |
Auspex Pharmaceuticals, Inc. |
Thioxanthene modulators of dopamine d2 receptors
|
US20100056546A1
(en)
|
2008-09-04 |
2010-03-04 |
Auspex Pharmaceuticals, Inc. |
Sulfonylurea inhibitors of atp-sensitive potassium channels
|
KR101641519B1
(ko)
|
2008-09-05 |
2016-07-21 |
그뤼넨탈 게엠베하 |
3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀과 항간질제의 약제학적 병용물
|
US20100190752A1
(en)
|
2008-09-05 |
2010-07-29 |
Gruenenthal Gmbh |
Pharmaceutical Combination
|
US20100105755A1
(en)
|
2008-09-12 |
2010-04-29 |
Auspex Pharmaceuticals, Inc. |
Substituted benzamide modulators of dopamine receptor
|
US20100119622A1
(en)
|
2008-09-15 |
2010-05-13 |
Auspex Pharmaceuticals, Inc. |
3h-benzooxazol-2-one modulators of d2 receptor and/or 5-ht1a receptor
|
US8436015B2
(en)
|
2008-09-15 |
2013-05-07 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
|
US20100119624A1
(en)
|
2008-09-17 |
2010-05-13 |
Auspex Pharmaceuticals, Inc. |
Benzisoxazole modulators of d2 receptor and/or 5-ht2a receptor
|
US20110244057A1
(en)
|
2008-09-25 |
2011-10-06 |
Ehrenberg Bruce L |
Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions
|
US20100159033A1
(en)
|
2008-09-29 |
2010-06-24 |
Auspex Pharmaceuticals, Inc. |
Benzisoxazole modulators of d2 receptor, and/or 5-ht2a receptor
|
US20100266711A1
(en)
|
2008-09-29 |
2010-10-21 |
Auspex Pharmaceuticals, Inc. |
Thienobenzodiazepine modulators of d1 receptor, d2 receptor, and/or 5-ht2 receptor
|
AU2009303979A1
(en)
|
2008-10-14 |
2010-04-22 |
Mcneil Ab |
Multi portion intra-oral dosage form and use thereof
|
US20100113583A1
(en)
|
2008-10-16 |
2010-05-06 |
Aronne Louis J |
Combination therapies for the treatment of obesity
|
US20100166887A1
(en)
|
2008-10-22 |
2010-07-01 |
Auspex Pharmaceuticals, Inc. |
DIBENZO[b,e][1,4]DIAZEPINE MODULATORS OF DOPAMINE RECEPTORS, SEROTONIN RECEPTORS, ADRENERGIC RECEPTORS, ACETYLCHOLINE RECEPTORS, AND/OR HISTAMINE RECEPTORS
|
US20100167988A1
(en)
|
2008-10-22 |
2010-07-01 |
Auspex Pharmaceuticals, Inc. |
Ethoxyphenylmethyl inhibitors of sglt2
|
US20100167989A1
(en)
|
2008-10-23 |
2010-07-01 |
Auspex Pharmaceuticals, Inc. |
Isopropoxyphenylmethyl inhibitors of sglt2
|
US20100113432A1
(en)
|
2008-11-05 |
2010-05-06 |
Auspex Pharmaceuticals, Inc. |
Phenothiazine modulators of d2 receptors and 5-ht2 receptors
|
US20100120861A1
(en)
|
2008-11-13 |
2010-05-13 |
Auspex Pharmaceuticals, Inc. |
Benzoic acid inhibitors of atp-sensitive potassium channels
|
US20100125085A1
(en)
|
2008-11-17 |
2010-05-20 |
Auspex Pharmaceuticals, Inc. |
Pyridoindole modulators of nmda receptor and acetylcholinesterase
|
EP2352722A4
(en)
|
2008-11-19 |
2012-07-25 |
Auspex Pharmaceuticals Inc |
DIPEPTIDYLPEPTIDASE IV HYDROXYADAMANTYL INHIBITORS
|
US20100130528A1
(en)
|
2008-11-21 |
2010-05-27 |
Auspex Pharmaceuticals, Inc. |
Adamantane modulators of nmda receptor and/or 5ht3 receptor
|
US20100130615A1
(en)
|
2008-11-21 |
2010-05-27 |
Auspex Pharmaceuticals, Inc. |
Sulfonylurea inhibitors of atp-sensitive potassium channels
|
US20100129311A1
(en)
|
2008-11-21 |
2010-05-27 |
Auspex Pharmaceuticals, Inc. |
Phenylalanine amide inhibitors of atp-sensitive potassium channels
|
US20100130582A1
(en)
|
2008-11-24 |
2010-05-27 |
Auspex Pharmaceuticals, Inc. |
Indolinone modulators of dopamine receptor
|
US20100143507A1
(en)
|
2008-12-09 |
2010-06-10 |
Auspex Pharmaceuticals, Inc. |
Carboxylic acid inhibitors of histone deacetylase, gaba transaminase and sodium channel
|
US20100159034A1
(en)
|
2008-12-15 |
2010-06-24 |
Auspex Pharmaceuticals, Inc. |
Pyrrolidinone inhibitors of pde-4
|
US8445538B2
(en)
|
2008-12-19 |
2013-05-21 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds
|
WO2010080976A1
(en)
|
2009-01-09 |
2010-07-15 |
Sdg, Inc. (An Ohio Corporation) |
Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
|
WO2010088061A1
(en)
|
2009-01-28 |
2010-08-05 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
|
US8324384B2
(en)
|
2009-02-12 |
2012-12-04 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
|
US8809579B2
(en)
|
2009-02-13 |
2014-08-19 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
WO2010098994A1
(en)
|
2009-02-25 |
2010-09-02 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
|
US9265764B2
(en)
|
2009-02-27 |
2016-02-23 |
Massachusetts Institute Of Technology |
Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
|
US20100286762A1
(en)
|
2009-03-18 |
2010-11-11 |
Musc Foundation For Research Development |
Compositions and Methods for Ameliorating Clinical Electrical Disturbances
|
US20120020954A1
(en)
|
2009-03-30 |
2012-01-26 |
Anat Achiron |
Methods of predicting clinical course and treating multiple sclerosis
|
WO2010118291A2
(en)
|
2009-04-10 |
2010-10-14 |
Auspex Pharmaceuticals, Inc. |
Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
|
JP2012526848A
(ja)
|
2009-05-14 |
2012-11-01 |
ギリアード サイエンシーズ, インコーポレイテッド |
Cns障害の治療のためのラノラジン
|
US20100317730A1
(en)
|
2009-06-12 |
2010-12-16 |
Shaya Elias K |
Treatment for menopausal and perimenopausal vasomotor symptons
|
WO2010147830A2
(en)
|
2009-06-15 |
2010-12-23 |
Auspex Pharmaceuticals, Inc. |
Aminothiazole modulators of beta-3-adrenoreceptor
|
WO2011008298A2
(en)
|
2009-07-16 |
2011-01-20 |
Nectid, Inc. |
Novel axomadol dosage forms
|
US20110014296A1
(en)
|
2009-07-17 |
2011-01-20 |
National Chiao Tung University |
Drug Delivery Nanodevice, its Preparation Method and Uses Thereof
|
WO2011009115A2
(en)
|
2009-07-17 |
2011-01-20 |
Metabolous Pharmaceuticals, Inc. |
Combination therapies for the treatment of obesity
|
US20110257260A1
(en)
|
2009-07-21 |
2011-10-20 |
Auspex Pharmaceuticals, Inc. |
3,4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor
|
US20110053914A1
(en)
|
2009-08-28 |
2011-03-03 |
Gruenenthal Gmbh |
Pharmaceutical Combination Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-Dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an Antiepileptic
|
EP2477610A1
(en)
*
|
2009-09-17 |
2012-07-25 |
Upsher-Smith Laboratories, Inc. |
A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug
|
DK2480669T3
(en)
|
2009-09-25 |
2018-02-12 |
Curna Inc |
TREATMENT OF FILAGGRIN- (FLG) RELATED DISEASES BY MODULATING FLG EXPRESSION AND ACTIVITY
|
US20110082407A1
(en)
|
2009-10-01 |
2011-04-07 |
Aronne Louis J |
Combination Therapies for the Treatment of Obesity
|
JP5965318B2
(ja)
|
2009-10-16 |
2016-08-03 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Dll4アンタゴニストおよび降圧剤の治療的併用およびそれらによる治療の方法
|
WO2011050008A2
(en)
|
2009-10-19 |
2011-04-28 |
Amylin Pharmaceuticals, Inc. |
Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders
|
EP2322163A1
(en)
|
2009-11-03 |
2011-05-18 |
Pharnext |
New therapeutics approaches for treating alzheimer disease
|
US20110117214A1
(en)
|
2009-11-16 |
2011-05-19 |
Auspex Pharmaceuticals, Inc. |
Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
|
AU2010330747B2
(en)
|
2009-12-18 |
2016-08-11 |
Achelios Therapeutics, Inc. |
Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
|
US20110206780A1
(en)
|
2010-01-06 |
2011-08-25 |
Auspex Pharmaceuticals, Inc. |
Morphinan modulators of nmda receptors, sigma1 receptors, sigma2 receptors, and/or a3b4 nicotinic receptors
|
CA2786026A1
(en)
|
2010-01-07 |
2011-07-14 |
Vivus, Inc. |
Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent
|
UY33173A
(pt)
|
2010-01-08 |
2011-07-29 |
Eurand Inc |
|
US8461171B2
(en)
|
2010-02-09 |
2013-06-11 |
QRxPharma Ltd. |
Hybrid opioid compounds and compositions
|
WO2011101866A2
(en)
*
|
2010-02-17 |
2011-08-25 |
Sun Pharma Advanced Research Company Ltd., |
A method of treating a disease condition susceptible to baclofen therapy
|
US20110206782A1
(en)
|
2010-02-24 |
2011-08-25 |
Auspex Pharmaceuticals, Inc. |
Piperidine modulators of dopamine receptor
|
WO2011107855A2
(en)
|
2010-03-04 |
2011-09-09 |
Torrent Pharmaceuticals Limited |
Sustained release oral liquid suspension dosage form
|
GB201003766D0
(en)
|
2010-03-05 |
2010-04-21 |
Univ Strathclyde |
Pulsatile drug release
|
GB201003731D0
(en)
|
2010-03-05 |
2010-04-21 |
Univ Strathclyde |
Immediate/delayed drug delivery
|
GB201003734D0
(en)
|
2010-03-05 |
2010-04-21 |
Univ Strathclyde |
Delayed prolonged drug delivery
|
WO2011114271A1
(en)
|
2010-03-19 |
2011-09-22 |
Pfizer Inc. |
2,3 dihydro-1h-inden-1-yl- 2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
|
WO2011120044A1
(en)
|
2010-03-26 |
2011-09-29 |
Duke University |
Conjugated neuroactive steroid compositions and methods of use
|
WO2011126910A2
(en)
|
2010-03-30 |
2011-10-13 |
Algynomics Inc. |
Compositions and methods for the treatment of somatosensory disorders
|
US9695264B2
(en)
|
2010-04-01 |
2017-07-04 |
Ppg Industries Ohio, Inc. |
High functionality polyesters and coatings comprising the same
|
NZ602921A
(en)
|
2010-05-05 |
2016-01-29 |
Boehringer Ingelheim Int |
Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
|
WO2011143721A1
(en)
|
2010-05-21 |
2011-11-24 |
Gosforth Centre (Holdings) Pty Ltd |
Compositions and methods for treating neurodegenerative disorders
|
EP2584899B1
(en)
|
2010-06-24 |
2018-01-10 |
Trustees Of Tufts College |
Niacin mimetics, and use thereof
|
US8450316B2
(en)
|
2010-06-24 |
2013-05-28 |
Trustees Of Tufts College |
Niacin mimetics, and methods of use thereof
|
US20120003312A1
(en)
|
2010-06-30 |
2012-01-05 |
Aptapharma, Inc. |
Multilayer Minitablets with Different Release Rates
|
EP2422787A1
(en)
|
2010-08-17 |
2012-02-29 |
Neurotec Pharma, S.L. |
Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als)
|
WO2012033874A1
(en)
|
2010-09-10 |
2012-03-15 |
Chipkin Richard E |
Method of treating compulsive self-injurious behaviors
|
SI2632925T1
(sl)
|
2010-10-29 |
2015-07-31 |
Pfizer Inc. |
Inhibitorji N1/N2-laktam acetil-CoA karboksilaze
|
AU2011326173B2
(en)
|
2010-11-08 |
2015-08-27 |
Omeros Corporation |
Treatment of addiction and impulse-control disorders using PDE7 inhibitors
|
WO2012074561A2
(en)
|
2010-11-30 |
2012-06-07 |
Columbia Northwest Pharmaceuticals Llc |
Methods and compositions for the treatment of anxiety disorders, including post traumatic stress disorder (ptsd) and related central nervous system (cns) disorders
|
EP2479691A1
(en)
|
2011-01-21 |
2012-07-25 |
Johan Cederlund |
Pharmaceutical product and communication tool
|
WO2012100347A1
(en)
|
2011-01-24 |
2012-08-02 |
Inceptum Research & Therapeutics, Inc. |
Compositions comprising a prostaglandin for treating neuropsychiatric conditions
|
US20140050728A1
(en)
|
2011-01-28 |
2014-02-20 |
Board Of Regents Of The University Of Nebraska |
Methods and compositions for inhibiting cyclophilin d for the treatment and prevention of obesity and kidney indications
|
US20120128683A1
(en)
|
2011-11-22 |
2012-05-24 |
Shantha Totada R |
Autism treatment
|
US8652527B1
(en)
*
|
2013-03-13 |
2014-02-18 |
Upsher-Smith Laboratories, Inc |
Extended-release topiramate capsules
|
US9101545B2
(en)
*
|
2013-03-15 |
2015-08-11 |
Upsher-Smith Laboratories, Inc. |
Extended-release topiramate capsules
|